Results 111 to 120 of about 874,981 (155)

Anti-IL 23 biologics for the treatment of plaque psoriasis

Expert Opinion on Biological Therapy, 2022
Psoriasis is a chronic inflammatory disease that can drastically affect a patient's quality-of-life and is associated with multiple comorbid conditions. The most common form of psoriasis is plaque psoriasis, commonly presenting as sharply demarcated, erythematous plaques with overlying silvery scale on the trunk, extensor surfaces, limbs, and scalp ...
Alan Vu, Caden Ulschmid, Kenneth B. Gordon   +2 more
openaire   +2 more sources

A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.

Expert Opinion on Biological Therapy, 2017
Psoriasis is a chronic inflammatory skin disease whose pathogenesis is driven by multiple cytokine-mediated pathways. In this immunologic setting, the centrality of the IL-23/IL-17 axis and its therapeutic relevance has emerged.This review is aimed at collecting preliminary data on IL23p19 blockers developed for the treatment of plaque psoriasis. Three
Tonini, Annalisa, Gualtieri, Bruno, Panduri, Salvatore, Romanelli, Marco, Chiricozzi, Andrea   +4 more
openaire   +4 more sources

Anti-IL-23 Phase II Data for Psoriasis: A Review.

Journal of drugs in dermatology : JDD, 2016
Monoclonal antibodies that target both Interleukin (IL)-12 and IL-23 have shown great efficacy in the treatment of psoriasis. Recent evidence suggests that IL-23 serves a more critical role than IL-12 in the pathogenesis of psoriasis, leading to the development of monoclonal antibodies that specifically target IL-23.We reviewed the results of the phase
Kourosh, Beroukhim, Melissa J, Danesh, Catherine, Nguyen, Annemieke, Austin, John, Koo, Ethan, Levin   +5 more
openaire   +1 more source

IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody

Clinical Journal of Gastroenterology
Interleukin-17 (IL-17) has been suggested to have a protective effect on the intestinal mucosa. The administration of an anti-IL-17 receptor monoclonal antibody has been associated with the onset of inflammatory bowel disease. We present a case of ulcerative colitis caused by secukinumab, an anti-IL-17 receptor A monoclonal antibody, that was treated ...
Natsuki Ishida, Yusuke Asai, Tomohiro Takebe, Kenichi Takahashi, Kiichi Sugiura, Tomoharu Matsuura, Kazuo Kurihara, Takahiro Suzuki, Tetsuya Honda, Ken Sugimoto   +9 more
openaire   +2 more sources

Landscape of anti-IL-23 therapy in inflammatory bowel disease: recent advances

Frontline Gastroenterology
Inflammatory bowel disease (IBD) commonly requires advanced therapies to induce and maintain durable remission. Interleukin (IL)-23 is a proinflammatory heterodimeric cytokine composed of a p40 subunit, which is shared with IL-12 and a unique p19 subunit.
Michael Colwill, Jennifer Clough, Samantha Baillie, Kamal Patel, Laurent Peyrin-Biroulet, Sailish Honap   +5 more
openaire   +1 more source

ANTI-IL-23 ANTIBODIES

2021
NABOZNY GERALD HENRY, GALLER ANNETTE BETTINA, GARIDEL PATRICK, LOGING WILLIAM TROY, PADULA STEVEN JOHN, SCHULTZ-FADEMRECHT TORSTEN, WANG ELAINE EE-LING   +6 more
openaire   +2 more sources

045 Anti-IL-23 preferentially inhibits pathogenic TH17 cells

Journal of Investigative Dermatology, 2023
Seiringer, P., Eyerich, S., Ranzinger, D., Eyerich, K., Thomas, J., Pilz, A.C.   +5 more
openaire   +2 more sources

Resistance Mechanisms to Anti-PD Cancer Immunotherapy

Annual Review of Immunology, 2022
Matthew D Vesely, Lieping Chen
exaly  

Luminescence anti-counterfeiting: From elementary to advanced

Aggregate, 2021
Hongyue Zhang, Yu Jihong, Xiaowei Yu
exaly  

Medical device for administering anti-IL-23 antibodies

2021
BENSON JACQUELINE, CARTON JILL, CUNNINGHAM MARK, ORLOVSKY YEVGENIYA, RAUCHENBERGER ROBERT, SWEET RAYMOND   +5 more
openaire   +2 more sources